Literature DB >> 32336176

Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.

Ahmed Sawas1, Helen Ma1, Andrei Shustov2, Pamela Hsu3, Gajanan Bhat3, Mark Acosta4, Steven Horwitz5, Owen A O'Connor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32336176      PMCID： PMC8992838          DOI： 10.1080/10428194.2020.1753044

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview.

Authors:  E Sabattini; F Bacci; C Sagramoso; S A Pileri
Journal:  Pathologica       Date:  2010-06

2.  Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress.

Authors:  Yang W Zhang; Zhihong Wang; Wenbing Xie; Yi Cai; Limin Xia; Hariharan Easwaran; Jianjun Luo; Ray-Whay Chiu Yen; Yana Li; Stephen B Baylin
Journal:  Mol Cell       Date:  2017-01-19       Impact factor: 17.970

3.  Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

Authors:  François Lemonnier; Jehan Dupuis; Pierre Sujobert; Olivier Tournillhac; Morgane Cheminant; Clémentine Sarkozy; Laura Pelletier; Ambroise Marçais; Cyrielle Robe; Virginie Fataccioli; Corinne Haioun; Olivier Hermine; Philippe Gaulard; Richard Delarue
Journal:  Blood       Date:  2018-10-02       Impact factor: 22.113

4.  Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.

Authors:  Owen A O'Connor; Lorenzo Falchi; Jennifer K Lue; Enrica Marchi; Cristina Kinahan; Ahmed Sawas; Changchun Deng; Francesca Montanari; Jennifer E Amengual; Hye A Kim; Aishling M Rada; Karen Khan; Alice T Jacob; Michelle Malanga; Mark M Francescone; Renu Nandakumar; Craig R Soderquist; David C Park; Govind Bhagat; Bin Cheng; Alberto Risueño; Daniel Menezes; Andrei R Shustov; Lubomir Sokol; Luigi Scotto
Journal:  Blood       Date:  2019-10-24       Impact factor: 22.113

5.  Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

Authors:  Owen A O'Connor; Steven Horwitz; Tamás Masszi; Achiel Van Hoof; Peter Brown; Jeannette Doorduijn; Georg Hess; Wojciech Jurczak; Poul Knoblauch; Shanta Chawla; Gajanan Bhat; Mi Rim Choi; Jan Walewski; Kerry Savage; Francine Foss; Lee F Allen; Andrei Shustov
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

6.  RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.

Authors:  Jose R Cortes; Alberto Ambesi-Impiombato; Lucile Couronné; S Aidan Quinn; Christine S Kim; Ana C da Silva Almeida; Zachary West; Laura Belver; Marta Sanchez Martin; Laurianne Scourzic; Govind Bhagat; Olivier A Bernard; Adolfo A Ferrando; Teresa Palomero
Journal:  Cancer Cell       Date:  2018-02-02       Impact factor: 31.743

Review 7.  Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas.

Authors:  Mehdi Hamadani; Sarah M Abu Kar; Saad Z Usmani; Bipin N Savani; Ernesto Ayala; Mohamed A Kharfan-Dabaja
Journal:  Semin Hematol       Date:  2013-11-15       Impact factor: 3.851

Review 8.  Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review.

Authors:  Ahmed Sawas; Dejan Radeski; Owen A O'Connor
Journal:  Ther Adv Hematol       Date:  2015-08

9.  IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.

Authors:  Rob A Cairns; Javeed Iqbal; François Lemonnier; Can Kucuk; Laurence de Leval; Jean-Philippe Jais; Marie Parrens; Antoine Martin; Luc Xerri; Pierre Brousset; Li Chong Chan; Wing-Chung Chan; Philippe Gaulard; Tak W Mak
Journal:  Blood       Date:  2012-01-03       Impact factor: 25.476

10.  Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.

Authors:  Barbara Pro; Steven M Horwitz; H Miles Prince; Francine M Foss; Lubomir Sokol; Matthew Greenwood; Dolores Caballero; Franck Morschhauser; Martin Wilhelm; Swaminathan Padmanabhan Iyer; Andrei R Shustov; Julie Wolfson; Barbara E Balser; Bertrand Coiffier
Journal:  Hematol Oncol       Date:  2016-07-12       Impact factor: 5.271
View more
  1 in total

1.  Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.

Authors:  Yawen Wang; Mingzhi Zhang; Wei Song; Qingqing Cai; Liling Zhang; Xiuhua Sun; Liqun Zou; Huilai Zhang; Lili Wang; Hongwei Xue
Journal:  Am J Hematol       Date:  2022-03-11       Impact factor: 13.265
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.